Abeona Therapeutics (United States)

Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa

Shaundra Eichstadt, M. Barriga, Anusha Ponakala et al. · JCI Insight · 2019 · 107 citations · Full text

Medicine, Clinical Sciences, Dermatology +13

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity

Jianbo Dong, Betty Huang, Zhejun Jia et al. · Emerging Microbes & Infections · 2020 · 94 citations · Full text

Pharmacy, Infectious Diseases, Molecular Biology +17

Scalable synthesis and validation of PAMAM dendrimer‐<i>N</i>‐acetyl cysteine conjugate for potential translation

Rishi Sharma, Anjali Sharma, Siva P. Kambhampati et al. · Bioengineering & Translational Medicine · 2018 · 68 citations · Full text

Medicine, Medicinal Chemistry, Neuroscience +13

Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson’s Disease

Amirah E.-E. Aly, Brendan Harmon, Linas Padegimas et al. · Molecular Neurobiology · 2018 · 66 citations

Life Sciences, Neuroscience, Pharmacology +17

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa

Jodi So, Jaron Nazaroff, Chinonso V. Iwummadu et al. · Orphanet Journal of Rare Diseases · 2022 · 40 citations · Full text

Medicine, Clinical Sciences, Dermatology +16